Copyright
©The Author(s) 2020.
World J Gastrointest Pharmacol Ther. Nov 8, 2020; 11(5): 93-109
Published online Nov 8, 2020. doi: 10.4292/wjgpt.v11.i5.93
Published online Nov 8, 2020. doi: 10.4292/wjgpt.v11.i5.93
Figure 7 Early vascular presentation in and close to defect, before and immediately after therapy application.
A: Control rats. Illustrative presentation of the vessels in and close to the defect immediately before therapy (left), and immediately after therapy application at the abdominal cavity, under saline solution immersion (right). No particular vessel recruitment; B: BPC 157 rat. Illustrative presentation of the vessels in and close to the defect immediately before therapy (left), and immediately after therapy application at the abdominal cavity, under BPC 157 solution immersion (right). Particular vessel recruitment in and close to the defect.
- Citation: Berkopic Cesar L, Gojkovic S, Krezic I, Malekinusic D, Zizek H, Batelja Vuletic L, Petrovic A, Horvat Pavlov K, Drmic D, Kokot A, Vlainic J, Seiwerth S, Sikiric P. Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats. World J Gastrointest Pharmacol Ther 2020; 11(5): 93-109
- URL: https://www.wjgnet.com/2150-5349/full/v11/i5/93.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v11.i5.93